Breast cancer vaccine shows promise in small clinical trial — ScienceDaily
The study appears Dec. …
The study appears Dec. …
TNBC is deadly because, unlike other types of breast cancers such as estrogen receptor (ER) positive or HER2 amplified breast tumours which have effective targeted therapy, TNBC tumours do not respond to targeted therapy. Breast cancer has many subtypes, each with its own genetic makeup. …
TNBC is deadly because, unlike other types of breast cancers such as estrogen receptor (ER) positive or HER2 amplified breast tumours which have effective targeted therapy, TNBC tumours do not respond to targeted therapy. Breast cancer has many subtypes, each with its own genetic makeup. As such, different subtypes behave differently in invasion and metastasis. …
The immune system is designed to remove things not normally found in the body. Cells undergoing change, e.g…
“We expect that the new possibilities of immunotherapy will substantially change the treatment of cancer,” said Stahel, who is also Scientific Co-Chair of the meeting. “And this is not just in one disease, but across the board in many types of cancer…
In bean sprouts, a collection of amino acids known as a protein complex allows them to grow longer in the darkness than in the light. …
ASPS tumor cells contain a chromosomal translocation — strands of DNA from two chromosomes trade places. The two strands fuse together to create a new gene, ASPSCR1-TFE3 that functions differently than either “parent” gene…
The novel research shows that brain metastases have dense concentrations of tumour infiltrating lymphocytes, providing an immunoactive environment. Moreover, both primary and secondary brain cancers often exhibit high expression of the immunosuppressive factor programmed cell death ligand 1 (PDL1), which can be inhibited by new treatments, thus activating the immune system. …
The catalysts behind the formation of these deadly metastatic tumors are believed to be cancer cells that are launched into the bloodstream from the original site of the cancer. Researchers are very interested in leveraging these circulating tumor cells, or CTCs, which have the potential to allow the properties of a tumor to be better understood without a biopsy, and may also help physicians recognize how aggressive a tumor is and whether it is likely to cause metastatic disease. …
“One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells,” said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. “In the GAPVAC trial we will treat glioblastoma patients with vaccines that are ideal for each patient because they contain personalised antigens.”1 For all patients in the GAPVAC study, researchers will identify genes expressed in the tumour, peptides presented on the human leukocyte antigen (HLA) receptor (i.e…